Critical roles for Akt kinase in controlling HIV envelope-mediated depletion of CD4 T cells by Haishan Li & C Pauza
Li and Pauza Retrovirology 2013, 10:60
http://www.retrovirology.com/content/10/1/60RESEARCH Open AccessCritical roles for Akt kinase in controlling HIV
envelope-mediated depletion of CD4 T cells
Haishan Li and C David Pauza*Abstract
Background: The cell surface receptors CD4 and CCR5 bind CCR5-tropic HIV Envelope (Env) glycoprotein during
virus attachment. These same receptors have signaling activities related to normal immune cell functions. We also
know that Env binds to CCR5 present at high levels on CD4-negative γδ T cells where it signals through p38 MAP
kinase to activate caspases and Fas-independent cell death. Here, we asked whether Env signaling through cellular
receptors is responsible for death among uninfected CD4+/CCR5+ T cells and what are the effects of Env on CD4
+/CCR5-negative cells that might impact HIV infection. The outcomes of Env binding are analyzed in terms of
signal transduction and the effects on cell activation or cell death pathways.
Results: Env binding to CD4 signals through Erk and Akt kinases. Activation of Erk/Akt suppresses p38 due to CCR5
binding, and allows cell survival. When CD4 signaling was blocked by soluble CD4 or protein kinase inhibitors, p38
activation and Fas-independent cell death were increased among uninfected CD4+ CCR5+ T cells. We also noted
specific effects of CD4 signaling on CCR5-negative CD4 T cells in tonsil lymphocyte cultures. Exposure to CCR5-
tropic HIV Env (BaL strain) increased expression of CXCR5, PD-1, Fas and FasL. Among CD4+/CCR5- T cells
expressing high levels of CXCR5 and PD-1, there were substantial amounts of Fas-dependent cell death. Increased
CXCR5 and PD-1 expression was blocked by soluble CD4 or specific inhibitors of the Akt kinase, showing a direct
relationship between CD4 signaling, T cell activation and Fas-dependent cell death.
Conclusions: Specific inhibition of Akt activation increased Env-dependent cell death of CCR5+ CD4 T cells. The
same inhibitor, antibodies blocking the CD4 binding site on gp120, or soluble CD4 also prevented the increase in
expression of CXCR5 or PD-1, and reduced the levels of Fas-dependent cell death. The Akt kinase and related
signaling events, are key to cell survival that is needed for productive infection, and may be targets for the
development of antivirals. Specific inhibitors of Akt would decrease productive infection, by favoring cell death
during virus attachment to CD4+ CCR5+ target cells, and reduce immune activation to prevent Fas-dependent
death of uninfected CXCR5+ PD-1+ CD4 T cells including T follicular helper cells that share this phenotype.
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HIV disease is characterized by CD4 T cell depletion
and progressing immunodeficiency [1]. Because HIV in-
fects only a small proportion of CD4 T cells (estimated
at 0.1 ~ 1%) [2-4], much of the observed cell death
is due to indirect or bystander effects [4,5]. In fact, the
majority of T cells undergoing apoptosis in periphe-
ral blood, lymph nodes, thymus or spleen from HIV-
infected patients or SIV-infected macaques were not
infected [6-9]. Several mechanisms have been proposed* Correspondence: cdpauza@ihv.umaryland.edu
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reproduction in any medium, provided the orfor uninfected, bystander CD4 T cell depletion, including
direct action of HIV proteins, activation-induced cell
death, autologous cell-mediated cytotoxicity against un-
infected T cells, and dysregulation of cytokine/chemo-
kine production [4,10,11]. Several of these mechanisms
implicate HIV envelope (Env) glycoprotein as a pro-
moter of uninfected CD4 T cell depletion [12].
We wanted to understand the effects of CCR5-tropic
HIV Env signal transduction through CD4 or CCR5.
Normally, these signaling receptors are involved in
controlling immune responses. Env binding will also
trigger signal transduction and may affect HIV infec-
tion and virus replication. In fact, when R5-tropic EnvLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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p38 MAP kinase is activated, caspase activity increased
and Fas-independent cell death resulted [13,14]. It was
also reported that HIV Env glycoprotein (from HIV-1
strains IIIB, Bal, MN, JRFL, SF2 and SF162) induced
apoptosis of uninfected, CD4-negative neurons (strains
IIIB, SF2 and SF162) [15], cardiomyocytes (strain JR-FL)
[16], hepatocytes (strain MN) [17], proximal renal tubu-
lar cells [18], lung endothelial cells (strains BaL and
MN) [19] and human vascular endothelial cells [20].
The mechanisms for Env-induced cell death are contro-
versial [12,21,22]. Early studies proposed that oligomeric
or particle-associated Env cross-links CD4 which in-
creases spontaneous cell apoptosis, activation-induced
cell death and cell susceptibility to Fas-dependent
apoptosis [12]. Others argued against a direct role for
CD4 in the pathway for cell death. It was reported
that Env induced apoptosis only in T cell lines lac-
king a CD4 cytoplasmic domain [23] and Env mu-
tants that bind CXCR4 but do not bind CD4, still
induced apoptosis compared to mutants defective for
CXCR4 binding that did not cause cell death [24].
Env-dependent CD4 T cell death was blocked by CCR5
or CXCR4 binding antagonists [25-27] and soluble
CD4 (sCD4) increased R5 or X4-induced CD4 T cell
death [21,22].
Our studies focused on signal transduction events
driven by HIV Env binding to cell surface receptors on
tonsil CD4 T cells. We are defining discrete signaling
events after CD4 or CCR5 binding, and studying cross-
regulation among these pathways to learn more about
the function of each major HIV receptor beyond their
established roles in virus penetration. Receptor signaling
may be involved in both indirect cell death and the con-
trol of productive infection. By targeting protein kinases
involved in signal transduction, using small-molecule in-
hibitory drugs already in clinical development for cancer
therapy, we may identify new targets for antiretroviral
agents among host cell pathways.
Results
HIV R5-tropic Env induces tonsil CD4 T cell death
We first tested whether HIV R5 tropic Env kills human
tonsil CD4 T cells. Fresh, CD4 T cells were purified by ne-
gative selection from dissected human tonsils (Figure 1A).
We then used soluble gp120, cell-associated Env or virions
to test the killing effect of HIV Env. For soluble gp120,
purified CD4 T cells were treated with one of three soluble
R5-tropic HIV gp120 proteins: BaL (clade B), CN54 (B’/C
recombinant) or CM (clade E) at 10 μg/ml for 3 days. Cell
death was evaluated every 24 hours. Each of the soluble
gp120 proteins showed significant killing of CD4 T cells
(Figure 1B). By 24 hours, 5-10% of CD4 T cells were
killed which was significant compared to controls. Longerincubation times caused greater cell death. By 72 hours,
we observed 20-30% of CD4 T cells were dead. Signifi-
cant cell killing was also observed with soluble Env at 1
or 10 μg/ml. The effect was reduced at Env concentra-
tions below 1 μg/ml (Figure 1C).
We next examined the effects of cell- or virion-
associated HIV Env. A stable HeLa cell line expressing
HIV envelope from the ADA strain (HeLa-ADA) pro-
vided cell-associated Env. Cell lines HeLa or HeLa-ADA
were mixed in a ratio of 1:2 with purified tonsil CD4 T
cells. HeLa-ADA induced significant CD4 T cell death
compared with HeLa cell control at both early (24h) and
late times (72h) (Figure 1D). A pseudovirus expressing
HIV BaL Env and GFP was used to evaluate the effect of
virion-associated Env. Although only 2.4% of CD4 cells
became infected (Figure 1E), virion preparations induced
on average, 22% cell death within 72 hours (Figure 1F).
The fusion inhibitor T20 did not prevent cell killing by
either cell- or virion-associated Env (data not shown).
Distinct roles for CD4 and CCR5 in Env-induced CD4 T cell
death
We hypothesized that cell death induced by Env de-
pended on CD4 or CCR5-mediated signaling. To test
this idea, we blocked Env binding to CD4 with soluble
CD4 (sCD4) or neutralizing antibody VRC01 which tar-
gets the CD4 binding site on Env. Env-CCR5 binding
was blocked by the CCR5 antagonist Maraviroc or neu-
tralizing antibody 447-52D that blocks the co-receptor
binding site on Env. When Env-CD4 interactions were
blocked, cell death increased significantly (Figure 2).
Adding Maraviroc or antibody 447-52D at the start of
culture, reduced cell depletion at the 24 hour interval
(Figure 2).
CD4 and CCR5 mediated different signaling
We wanted to understand why blocking Env binding to
CCR5 inhibited but blocking Env-CD4 interactions actu-
ally increased cell death. We hypothesized that Env-CD4
binding induced survival signals that counteracted or
directly inhibited the death signal generated by Env bin-
ding to CCR5.
To test this hypothesis, we examined CCR5+ cell
depletion at 24 h. In our study, individual donors had
7-17% of tonsil CD4 T cells that also expressed CCR5+
(Figure 3A, D). The BaL-gp120 depleted on average,
55% of the CCR5+ CD4 T cells within 24 hours
(Figure 3A, D). Adding soluble CD4 or VRC01 mono-
clonal antibody increased the rate of CCR5+ cell loss,
while Maraviroc blocked cell depletion (Figure 3A, D).
We next examined signaling pathways activated when Env
binds to CD4 or CCR5. We confirmed that BaL-gp120 ac-
tivated Akt, Erk and p38 signaling in tonsil CD4 T cells
(Figure 3B). Soluble CD4 or VRC01 antibody inhibited
Figure 1 HIV R5-tropic Env induces tonsil CD4 T cell death. (A) Tonsil CD4 T cells were purified by negative selection. (B) Purified tonsil
CD4 T cells were treated with or without soluble gp120 (BaL, CN54 or CM) at 10 μg/ml (n = 7); or (C) treated with BaL-gp120 at different
concentrations (μg/ml); or (D) were cocultured with HeLa cells or HeLa cells expressing HIV ADA-envelope (HeLa-ADA) at a ratio of 1:2 (n = 4); or
(F) treated with pseudo virion expressing HIV BaL envelope and GFP at 50 ng/ml of p24 (n = 4) for 3 days. Cell death was evaluated every 24 hours.
The statistical significance was analyzed with Student’s t test; *P < 0.05, **P < 0.005, ***P < 0.0001. (E) Purified tonsil CD4 T cells were treated with
pseudo-viruses expressing HIV BaL envelope and GFP at 50 ng/ml of p24 for 24 hours. The GFP positive cells were detected by flow cytometry. Data
are representative of four independent experiments.
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p38 (Figure 3B). Maraviroc inhibited Env-dependent p38
activation, but did not affect Akt or Erk (Figure 3B).
Next, we used specific signal transduction inhibitors
to test the roles for individual pathways in Env-me-
diated killing of CD4 T cells. All inhibitors were used
at concentrations which had no measurable cytoto-
xicity. Adding Akt (LY294002) or Erk (U0126) inhibi-
tors increased Env-dependent CCR5+ cell depletion
(Figure 3C, D). When Akt and Erk inhibitors were
combined, nearly all CCR5+ cells were depleted after Env
exposure (Figure 3C, D). A p38 inhibitor (SB203580)reduced CCR5+ cell depletion (Figure 3C, D). These re-
sults support a mechanism for HIV Env-mediated killing
of uninfected CD4 T cells that depends on Env sig-
naling through CCR5, but that signal can be modu-
lated when Env binds CD4 and limits the extent of
cell death (Figure 3E).
A subset of CCR5-negative CD4 T cells in tonsil express
activation markers and are susceptible to Fas-mediated
killing
Aside from the susceptible CD4+ CCR5+ T cells, 30-60%
of tonsil CD4 cells express activation markers including
Figure 2 CD4 and CCR5 have different effects on HIV
Env-induced CD4 T cell death. Cell death was evaluated every
24 hours after purified tonsil CD4 T cells were incubated with
soluble HIV gp120 protein (BaL, 10 μg/ml) in the absence or presence
of blocking reagents for CD4 (sCD4 or VRC01, 20 μg/ml) or CCR5
(Maraviroc 1 μM; or 447-52D Ab 20 μg/ml) binding for 3 days (n = 7).
The statistical significance was analyzed. *P < 0.05, **P < 0.005,
***P < 0.0001 (Student’s t test).
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(Figure 4C). These activated subsets do not express CCR5
(Figure 4D) [28] and thus resist Env-CCR5-mediated kill-
ing. However, they do express high levels of Fas (Figure 4E)
and FasL (Figure 4F). Fas agonist antibody (CH11) in-
duced high levels of apoptosis (Figure 4G) and the effect
was blocked by Fas neutralizing antibody ZB4 (Figure 4H).
The frequency of highly activated T cells (CXCR5hiPD-1hi)
gradually declined during culture (from 36% to 18% in this
typical example, Figure 5A); by 3 days, ~50% of the acti-
vated T cells were lost; Fas neutralizing antibody ZB4
inhibited this cell loss (Figure 5A). We did not observe
significant changes in the frequency of less activated
T cells (CXCR5loPD-1lo) during this time course or after
treatments (Figure 5A).
HIV Env promotes activation and cell death among
CCR5-negative cells
Having found that highly activated CXCR5hiPD-1hi cells
are a major subset of tonsil CD4 T cells and are suscep-
tible to FasL-Fas-mediated apoptosis, we next wanted to
define the effects of HIV Env. Purified tonsil CD4 T cells
were incubated with or without BaL-gp120 for 3 days;
CXCR5 and PD-1 expression were monitored daily by
flow cytometry. Compared with controls, adding Env
glycoprotein increased the proportion of activated cells
by day 1, followed by a rapid decline in this subset on
days 2 and 3 (Figure 5A). BaL-gp120 also increased
the frequency of a less-activated subset at days 2 and 3
(Figure 5A). Soluble CD4 but not Maraviroc, preven-
ted Env activation of T cells, pointing to Env-CD4interactions as the major signaling mechanism. Since we
used a CCR5-tropic Env (BaL) we did not expect it to
bind CXCR4 on these activated T cells.
Because the activated cell subset (CXCR5hiPD-1hi) did
not express CCR5 [28], early (proportional) increases in
these cells might be due to the loss of CCR5+ T cells. To
test the direct effect of Env on activated cells, we purified
them and treated with BaL-gp120 for 3 days which en-
hanced expression of both CXCR5 and PD-1 (Figure 5B)
and slightly elevated Fas expression (Figure 5C). This
result shows that the increase in CXCR5loPD-1lo cells in
response to Env signaling was not due to phenotypic re-
version of highly active cells but was due to depletion of
the activated subset.
We asked whether Env:CD4-mediated Akt or Erk sig-
naling was required for CD4 T cell activation and espe-
cially for CXCR5 and PD-1 expression. We purified non-
activated (CXCR5- and PD-1-) cells and cultured them
with BaL-gp120. After 3 days, both CXCR5loPD-1lo (15%
of the total CD4 cells) and CXCR5hiPD-1hi T cells (7%)
(Figure 5D) were generated in these cultures; these cells
also expressed higher Fas (data not shown). Soluble CD4
but not Maraviroc prevented Env-induced cell activation
(Figure 5D). An inhibitor of Akt but not Erk phosphoryl-
ation, or a p38 inhibitor specifically blocked this pathway
(Figure 5D).
HIV Env binds and signals through CD4; the signal
leads to Akt phosphorylation and T cell activation with
higher expression of CXCR5 and PD-1. Along with higher
expression of Fas and FasL, these cells become more
prone to apoptosis. This mechanism links HIV Env sig-
naling with tonsil CD4 T cell death in CCR5-negative
subsets.
Discussion
We investigated the mechanisms for R5-tropic HIV Env-
induced killing of tonsil CD4 T cells. Env binding to
CCR5 activated p38 kinase and caspase resulting in
death of CCR5+ cells during the first 24 hours of cul-
ture. However, Env binding to CD4 triggered Akt/Erk
which modulated p38 activation and counteracted the
death signal. The outcome of Env binding to CCR5+
cells was a balance of survival (Akt, Erk) versus death
(p38) signaling. A distinct mechanism targeted CCR5-
negative cells and required CD4 signaling through Akt
pathways to promote T cell activation and cell killing by
Fas-dependent apoptosis. Thus, Env:CD4 interactions
(with CCR5-tropic Env glycoprotein) have different ef-
fects on CD4 cell subsets; first mitigating the impact of
CCR5 signaling to reduce rapid, Fas-independent cell
death and later promoting activation of CCR5-negative
T cells leading to Fas-dependent cell death.
Previous studies showing that sCD4 enhanced HIV
Env-induced CD4 T cell death [21,22], explained that
Figure 3 CD4 and CCR5 mediated different signaling. (A) Purified tonsil CD4 T cells were incubated with soluble HIV gp120 protein (BaL,
10 μg/ml) in the absence or presence of VRC01 (20 μg/ml), sCD4 (20 μg/ml) or Maraviroc (1 μM) for 24 hours (n = 4). Frequency of CCR5+ cells
was measured by flow cytometry. The statistical significance was analyzed. *P < 0.05, **P < 0.005, ***P < 0.0001 (Student’s t test). (B) Purified tonsil
CD4 T cells were incubated with or without BaL-gp120 for 1 h on ice. Thereafter, cells were incubated at 37°C for 2 minutes to induce stimulation.
(C) Purified tonsil CD4 T cells were untreated or pretreated with specific inhibitors (2μM) for Akt (LY294002), Erk (U0126) or p38 (SB203580) for 1 hour
at 37°C before incubated with BaL gp120 (10 μg/ml) for 24 hours (n = 4). Frequency of CCR5+ cells was measured by flow cytometry. The statistical
significance was analyzed. *P < 0.05, **P < 0.005, ***P < 0.0001 (Student’s t test). (D) A representative result of CCR5+ cells in tonsil CD4 T cells in
different culture conditions as described above for 24 hours. (E) A proposed model based on our findings that Env-CD4 binding induced survival
signals (Akt and Erk) that counteracted or directly inhibited the death signal (p38) generated upon Env binding to CCR5.
Li and Pauza Retrovirology 2013, 10:60 Page 5 of 10
http://www.retrovirology.com/content/10/1/60sCD4 induced gp120 conformational changes that were
required for chemokine receptor binding. At 1 μg/ml,
gp120 is present at approximately 10-fold molar excess
above cell surface CD4 receptors, and 100-fold molar
excess above cell surface CCR5. gp120 binding to cell
surface CD4 gains an advantage through avidity, for
binding CCR5. If this advantage is only 10-fold, a very
conservative estimate, gp120 bound to CD4 will out-
compete solution gp120 for CCR5 binding, whether so-
lution gp120 is bound to sCD4 or not. Consequently,
gp120 bound to cell surface CD4 likely has a significant
advantage over soluble CD4 for binding to CCR5, ir-
respective of the dissociation constants and even when
sCD4 is in great excess.
Our study indicated that signaling through CD4, with
activation of Akt/Erk kinase, actually modulates killing
of CCR5+ cells. When Akt/Erk signaling is blocked by
sCD4, VRC01 or specific inhibitors, the p38 death signal
became stronger and cell death are more prominent be-
cause the tempering effect of signaling through cell sur-
face CD4 is not present. During HIV attachment, gp120
binds CD4 and then CCR5 to initiate the entry pathway.
In our view, viral evolution to CD4 binding may be a
mechanism for modulating cell death due to chemokinereceptor engagement; this adaptation increased the effi-
ciency of infection and overall viral virulence. A mecha-
nism that protects CD4+/CCR5+ T cells from indirect
depletion, preserves this CD4 subset and positively se-
lects for highly transmissible, CCR5-tropic HIV.
Another consequence of Env:CD4 signaling is T cell
activation leading to Fas-mediated cell killing among
CCR5-negative cells that escaped direct, p38-mediated
killing. Where and when this occurs in vivo are key
questions. During viremic HIV infection, it was estima-
ted that soluble gp120 levels in blood ranged between
120–960 ng/ml and total gp120, including soluble, virion
and cell-associated forms, is between 500 ng/ml and
5 ug/ml [29-33]. We expect local concentrations of
gp120 in lymph nodes to be higher, especially around
germinal centers where antigen normally accumulates.
Virological synapses form during the attachment pro-
cess, leading to co-localization of Env, CD4 and corecep-
tors that will further exaggerate signaling mechanisms
beyond what we observe with soluble gp120. Conse-
quently, lymphoid tissue CD4 T cells likely encounter
soluble or virion-associated Env at concentrations suffi-
cient to promote death of uninfected bystander cells.
We showed that Env treatment increased CXCR5 and
Figure 4 Germinal center CXCR5 + PD-1+ CD4 T cells are susceptible to Fas-mediated cell death. (A) Tonsil CD4 T cell subsets were
characterized on the basis of CXCR5 and PD-1 expression. (B-F) Expression levels of ICOS, CD69, CCR5, Fas or FasL on subsets were examined by
flow cytometry. (G, H) Purified tonsil CD4 T cells were treated with or without active anti-Fas antibody CH11 (1 μg/ml), or neutralizing anti-Fas
antibody ZB4 (1 μg/ml), or both for 8 hours (G) or 24 hours (H). Cell apoptosis was determined by expression of Annexin V (G) and the frequency
of different subsets was measured by expression of CXCR5 and PD-1 (H). Data are representative of three independent experiments.
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kers of T cell activation and also important for defining
the T follicular helper cell (TFH) subset that is crucial
for B cell differentiation and antibody production. Env
glycoprotein, accumulating to high levels around ger-
minal centers, would signal through CD4 and promote
activation of TFH cells. Indeed, recent papers linked the
accumulation of lymph node TFH with HIV disease.
Among HIV-infected patients, viremia was associated
with a shift in the distribution of lymph node CD4 cells
with substantially elevated TFH subsets [34]. Increased
TFH were coincident with hypergammaglobulinemia, a
recognized consequence of HIV infection [35,36]. In
SIV-infected macaques, lymph node TFH were elevated
and also linked to higher antibody production [37]. If
Env glycoprotein signaling contributes to the increased
levels of TFH in lymph nodes, it might also promote
CD4 cell depletion by increasing susceptibility to Fas:
FasL induced cell death. This mechanism can be tar-
geted with specific inhibitors of Akt activation.
Our system used purified tonsil CD4 T cells and
CCR5-tropic HIV Env. Others tested a model for abortive
infection of CXCR4+ tonsil CD4 cells where cytoplasmicviral DNA triggered a cell death pathway [38]. To avoid
abortive infection, in our experiments, we used soluble
gp120 and purified CD4 T cells; this allowed us to observe
the unusual effects of Env-dependent Akt activation, and
how we might exploit these pathways in new therapies.
However, it will be important to learn whether identifiable
CD4 T cell subsets may vary in their susceptibility to indi-
vidual cell death pathways.
Conclusions
We identified roles for Akt, Erk and p38 kinases in death
of uninfected CD4+ T cells in vitro. Specific binding, sig-
nal transduction and protein kinase inhibitors were used
to block pathologic effects of Env glycoprotein. Our
studies emphasize the importance of focusing on Akt
and Erk inhibitors to block CD4-dependent survival
signaling and render cells more susceptible to CCR5-
dependent cell killing. These same inhibitors prevented
T cell activation that might be related to TFH over-
production in lymph nodes during HIV infection. Inhibi-
tors of Akt and Erk are already being used in therapies
for cancer and autoimmune diseases; they may have
value for treating HIV disease.
Figure 5 Env-dependent CD4-mediated activation of Akt increases CXCR5/PD-1 expression and Fas-dependent cell death. (A) Purified
tonsil CD4 T cells were treated with or without BaL-gp120 for 3 days. In some cases, neutralizing anti-Fas antibody ZB4 (1 μg/ml), sCD4
(10 μg/ml) or Maraviroc (1 μM) was added to the T cell cultures. Expression of CXCR5 and PD-1 were monitored every day by flow cytometry.
(B, C) CXCR5hiPD-1hi cells were purified by cell sorting and cultured in the absence or presence of BaL-gp120 for 3 days. Expression of CXCR5,
PD-1 (B), or Fas (C) was detected by flow cytometry. (D) CXCR5-PD-1- cells were purified by cell sorting and cultured in the absence or presence of
BaL-gp120 for 3 days. In some cases, sCD4 (10 μg/ml), Maraviroc (1 μM), or specific inhibitors (2 μM) for Akt, Erk or p38, were added to cell cultures.
Expression of CXCR5 and PD-1 were detected by flow cytometry. Data are representative of three independent experiments.
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Tonsil cell isolation and tumor cell lines
Studies described here were approved by the Institu-
tional Review Board at the University of Maryland,
Baltimore. Tonsil samples were obtained from pa-
tients undergoing tonsillectomy. Single cells were col-
lected after mechanical disruption of dissected tonsil
and purification of mononuclear cells on density gra-
dients (Ficoll-Paque; Amersham Biosciences). CD4
T cells were isolated by negative selection (MiltenyiBiotech). On average, 15% of total CD4 T cells from
tonsil also expressed CCR5. Purified tonsil cells were
cultured in RPMI 1640 supplemented with 10% fetal
bovine serum (FBS; GIBCO), 2 mMol/L L-glutamine,
and penicillin–streptomycin (100 U/ml and 100 mg/mL,
respectively). HeLa cell lines were cultured in DMEM
supplemented with 10% fetal bovine serum (FBS; GIBCO),
2 mMol/L L-glutamine, and penicillin–streptomycin
(100 U/ml and 100 mg/mL, respectively). For HeLa-
ADA cells expressing an R5 tropic HIV envelope
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tion of 2 μM.
Preparation of pseudovirus and virus stocks
Pseudoviruses were prepared by co-transfecting 293 cells
with an HIV BaL Env expression plasmid and HIV back-
bone plasmid expressing the entire HIV genome except
Env (pNL4-3Δenv) with the aid of Lipofectamine™ 2000
(Invitrogen) according to the manufacturer's instruc-
tions. Pseudovirus stocks were harvested 48 hours after
transfection, filtered (0.45-μm pore size), concentrated
and stored at −80°C until used.
Reagents
The following reagents were obtained through the AIDS
Research and Reagent Program, Division of AIDS,
NIAID, NIH: HIV CN54 gp120 from Dr. Ian Jones, HIV
CM gp120 (Cat #2968), HIV gp120 MAb 447-52D, HIV
gp120 MAb VRC01 from Dr. John Mascola, and the
CCR5 binding antagonist drug Maraviroc (Cat # 11580).
Other monoclonal antibodies include: activating Fas Ab
(clone CH11, Millipore, Billerica, MA USA), blocking
Fas Ab (clone ZB4, Millipore, Billerica, MA USA). PI3K/
Akt inhibitor LY294002, Erk1/2 inhibitor U0126 and
P38 inhibitor SB203580 were from Cell Signaling Tech-
nology, Inc., Danvers, MA.
Cell death assays
The method was described previously [13]. Briefly, HeLa
or HeLa-ADA cells were resuspended and mixed with
purified CD4 T cells at 105 HeLa cells: 2 × 105 CD4
T cells, then plated in triplicate on 96-well plates for
3 days. The BaL (kindly provided by Dr. Tim Fouts,
Profectus Biosciences, Baltimore, MD), CN54 or CM
(NIH AIDS Research and Reference Program) gp120
proteins were added to 2 × 105 CD4 T cells at varying
concentrations in 96-well plates. After 3 days of culture,
assays for cell death were done in triplicate and repli-
cated with multiple, unrelated donors. For blocking
studies against CD4 or CCR5, CD4 T cells were incu-
bated with blocking reagents or antibodies for 1 hour at
37°C before adding to the killing assay. For inhibition
studies with anti-gp120 antibodies, gp120 were pretrea-
ted with specific antibodies for 30 minutes at room tem-
perature, then the mixtures were added to target cells
for cytotoxicity assays. Signaling involved in cell killing
was defined with specific inhibitors; CD4 T cells were
incubated with signal transduction inhibitors for 1 hour
at 37°C before the killing assay. The percentage of cell
mortality was calculated according to the number of
viable cells able to exclude trypan blue dye as follows:
1 – (total number of cells viable on day 2/total number
of cells viable on day 1 immediately after stimulation) ×
100. Cell death was confirmed with a cell death detectionELISA kit (Roche Diagnostics) or flow cytometry–based
methods with AnnexinV and 7AAD staining.
Immunoblot analysis
CD4 T cells were incubated with or without BaL-gp120
for 1 hour on ice. Thereafter, cells were incubated at
37°C for 2 minutes to induce stimulation. For blocking
assays, cells were pretreated with Maraviroc for 30
minutes, or BaL-gp120 were pretreated with sCD4 for
30 minutes. Cell lysates were boiled for 10 minutes;
proteins were separated by SDS-PAGE, transferred to
nitrocellulose membranes and probed with primary anti-
bodies. Secondary antibodies including HRP-conjugated,
anti-rabbit, anti-rat, or anti-mouse (Cell Signaling Tech-
nology, Inc.), were visualized with enhanced chemilu-
minescence (GE Healthcare, Buckinghamshire, UK).
Flow cytometry
Unless noted, cells were stained with fluorophore-con-
jugated monoclonal antibodies from BioLegend, San
Diego, CA. Generally, cells were washed and resus-
pended in 50–100 μL of RPMI 1640, then stained with
mouse anti-human CD4 (PE or FITC) clone OKT4,
mouse anti-human CD3 (APC) clone UCHT1, Mouse
anti-human PD-1 (FITC or APC) clone Eh12.2h7, mouse
anti human CXCR5 (PerCP, BD Bioscience) clone Tg2/
cxcr5, mouse anti-human ICOS (FITC) clone C398.4A,
mouse anti-human CD69 (APC, BD Bioscience) clone
Fn50, mouse anti-human CCR5-(APC, BD Bioscience)
clone 2d7, mouse anti-human Fas (PE, BD Bioscience)
clone Dx2, mouse anti-human FasL (PE) Nok-1 and
isotype controls, including mouse IgG1-FITC clone X40,
IgG1-PE clone X40, IgG1-PerCP clone X40, IgG1-APC
clone X40, and Mouse IgG2b PerCP clone Mpc-11. Cells
were stained to detect AnnexinV (PE) or 7AAD in
Annexin V binding buffer. Data for at least 1 × 104
lymphocytes (gated on the basis of forward- and side-
scatter profiles) were acquired from each sample on a
FACSCalibur flow cytometer (BD Biosciences). All
samples were analyzed using FlowJo software (FlowJo
8.8.2, Tree Star, San Carlos, CA).
Statistical analysis
Differences among groups were analyzed by Student’s
t test. P < 0.05 was considered to be significant.
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